Grand Pharmaceutical Group Management
Management criteria checks 2/4
Grand Pharmaceutical Group's CEO is Chao Zhou, appointed in Jun 2021, has a tenure of 2.92 years. directly owns 0.008% of the company’s shares, worth HK$1.14M. The average tenure of the management team and the board of directors is 2.9 years and 4.2 years respectively.
Key information
Chao Zhou
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.9yrs |
| CEO ownership | 0.008% |
| Management average tenure | 2.9yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Apr 25
Grand Pharmaceutical Group (HKG:512) Will Pay A Larger Dividend Than Last Year At HK$0.26
Mar 25We Think Grand Pharmaceutical Group (HKG:512) Can Stay On Top Of Its Debt
Oct 20Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Sep 26Grand Pharmaceutical Group's (HKG:512) Dividend Will Be Increased To HK$0.14
Jun 04Is Grand Pharmaceutical Group (HKG:512) A Risky Investment?
May 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Nov 21Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 43% Discount?
Sep 05Grand Pharmaceutical Group (HKG:512) Seems To Use Debt Quite Sensibly
Aug 16Here's Why We Think Grand Pharmaceutical Group (HKG:512) Is Well Worth Watching
Jul 28Grand Pharmaceutical Group's (HKG:512) Dividend Will Be HK$0.11
May 29Is Grand Pharmaceutical Group Limited (HKG:512) Trading At A 45% Discount?
Apr 08Grand Pharmaceutical Group (HKG:512) Has A Rock Solid Balance Sheet
Mar 22If You Like EPS Growth Then Check Out Grand Pharmaceutical Group (HKG:512) Before It's Too Late
Jan 24These 4 Measures Indicate That Grand Pharmaceutical Group (HKG:512) Is Using Debt Safely
Dec 13Grand Pharmaceutical Group Limited's (HKG:512) Intrinsic Value Is Potentially 45% Above Its Share Price
Nov 27With EPS Growth And More, China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Interesting
Oct 25China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Seems To Use Debt Rather Sparingly
Sep 01Do China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Warrant Your Attention?
Jul 12We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Can Stay On Top Of Its Debt
Apr 26Calculating The Fair Value Of China Grand Pharmaceutical and Healthcare Holdings Limited (HKG:512)
Apr 08Here's Why We Think China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Is Well Worth Watching
Mar 24If You Had Bought China Grand Pharmaceutical and Healthcare Holdings (HKG:512) Shares Five Years Ago You'd Have Earned 332% Returns
Mar 11Are Robust Financials Driving The Recent Rally In China Grand Pharmaceutical and Healthcare Holdings Limited's (HKG:512) Stock?
Feb 22China Grand Pharmaceutical and Healthcare Holdings's (HKG:512) Earnings Are Growing But Is There More To The Story?
Jan 21CEO
Chao Zhou (33 yo)
2.9yrs
Tenure
Mr. Chao Zhou serves as Executive Deputy Officer of Grand Pharmaceutical Group Limited (formerly known as China Grand Pharmaceutical and Healthcare Holdings Limited) since June 2019 and serves as its Chief...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 2.9yrs | HK$2.91m | 0.012% HK$ 1.8m | |
| Executive Director | 2.9yrs | HK$1.01m | no data | |
| CEO, Executive Deputy Officer & Executive Director | 2.9yrs | no data | 0.0075% HK$ 1.1m | |
| Investor Relations Director | no data | no data | no data | |
| Executive Director | less than a year | no data | no data | |
| Company Secretary | 12.7yrs | no data | no data | |
| Chairman of Grand Pharm (China) | no data | no data | no data | |
| Vice President | no data | no data | no data |
2.9yrs
Average Tenure
50.5yo
Average Age
Experienced Management: 512's management team is considered experienced (2.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 2.9yrs | HK$2.91m | 0.012% HK$ 1.8m | |
| Executive Director | 2.9yrs | HK$1.01m | no data | |
| CEO, Executive Deputy Officer & Executive Director | less than a year | no data | 0.0075% HK$ 1.1m | |
| Executive Director | less than a year | no data | no data | |
| Chairman of Grand Pharm (China) | no data | no data | no data | |
| Independent Non-Executive Director | 19.2yrs | HK$209.00k | no data | |
| Independent Non-Executive Director | 5.4yrs | HK$116.00k | no data | |
| Independent Non-Executive Director | 13yrs | HK$70.00k | no data | |
| Director of Grand Pharm (China) | 30.3yrs | no data | no data | |
| Director of Zhejiang Xianju Xianle Pharmaceutical Company Limited | no data | no data | no data |
4.2yrs
Average Tenure
57.5yo
Average Age
Experienced Board: 512's board of directors are considered experienced (4.2 years average tenure).